Thomas Rugino, M.D.

Subspecialty
Board Certified: American Academy of Pediatrics Neurodevelopmental Disabilities
Board Certified: American Board of Physical Medicine and Rehbabilitation
American Board of Psychiatry and Neurology

Program
Cerebral palsy, neuromuscular problems, spinal cord rehabilitation, ADHD, autism, learning disabilities, behavioral

Medical Degree
SUNY Downstate Medical Center

Academic Appointments
Associate Professor of Pediatrics, Marshall University School of Medicine, WV
Clinical Assistant Professor, West Virginia University School of Medicine
Clinical Assistant Professor, University of California at Irvine School of Medicine
Clinical Instructor, New York University School of Medicine

Other Hospital Appointments
Tustin Rehabilitation Hospital/Western Neuro Care Center
Kessler Institute for Rehabilitation
New York University Medical Center

Memberships
American Board of Pediatrics
American Academy of Cerebral Palsy & Developmental Medicine

Professional Associations
American Acadey of Pediatrics
American Academy of Cerebral Palsy & Developmental Medicine

Awards
Francis Black Humanitarian Award in Healthcare recipient presented by Friends’ Health Connection
Best Doctors in America 2009-2010

Other
Medical Director of the Parent Partners in Education Program – funded by a grant from the Developmental
Disabilities Planning council and WV Health and Human Services

Research
Consultant and primary investigator for Forest Protocol MEM-MD-57A: "An Open-label (Part One) and a Randomized, Double-blind, Placebo-Controlled (Part Two) Study of the Pharmacokinetics, Safety, Efficacy, and Tolerability of Memantine in Pediatric Patients with Autism."
Primary investigator for Shire Protocol SPD489-305: "Phase III, Randomized, Double-blind, Multi-Center, Parallel-Group, Placebo-Controlled, forced-Dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 with Attention-Deficit/Hyperactivity Disorder (ADHD)."
Primary investigator for Shire Protocol SPD502-313: "Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)."
Co-author and primary investigator for Lixicor protocol 004-1.5 "Best estimate diagnosis used to evaluate EEG in association with ADHD in a multi-site, clinical sample of children and adolescents."
Dr. Rugino has been involved in many research studies involving children with ADHD
Primary investigator for Eli Lilly Protocol FIJ-MC-HMFN "An open label study of tolerability, safety, and pharmacokinetics of duloxdetine in the treatment of children and adolescents with major depressive disorder."

Publications
Rugino TA, et al:Modafinil in Children with ADHD: A Double Blind, Placebo controlled Randomized Study; Pediatr Neurol: August 2003; 29(5): 136-142
Rugino TA, et al: Effects of Modafinil in Children with Attention-Deficit/Hyperactivity Disorder: An Open Label Study J. Am Acad Child Adolesc Psych; Feb 2001: 40(2): 230-235

Presentations
Intranasal Ipratropium Bromide in the Drooling Patient – MUSCOM Research Day – best clinical research award
Intravesical Oxybutynin: An Alternative to Systemic Dosing – American Spinal Injury Association Annual Meeting
Modafinil As Treatemtn for Children with Attention-Deficit/Hyperactivity Disorder – American College of Neuropsychopharmacology Convention